Sunitinib

證據等級: L5

預測適應症: 10 個

Sunitinib: From Established Tyrosine Kinase Inhibitor Indications to Liposarcoma

One-Sentence Summary

Sunitinib is a multi-targeted tyrosine kinase inhibitor with well-established use in gastrointestinal stromal tumour, advanced renal cell carcinoma, and pancreatic neuroendocrine tumour. The TxGNN model predicts it may also be effective for Liposarcoma, with 3 clinical trials and 9 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not available in local licensing data (drug not marketed in this jurisdiction); publicly known original indications include gastrointestinal stromal tumour, advanced renal cell carcinoma, and pancreatic neuroendocrine tumour
Predicted New Indication	Liposarcoma
TxGNN Prediction Score	99.87%
Evidence Level	L2
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available in this evidence pack. Based on publicly known information, sunitinib is a multi-targeted receptor tyrosine kinase inhibitor acting on VEGFR1-3, PDGFRα/β, KIT, FLT3, and RET, and its efficacy in angiogenesis- and kinase-driven cancers such as GIST and renal cell carcinoma is well established.

Liposarcoma — particularly the myxoid subtype — shows angiogenesis dependence and partial PDGFR pathway activation, giving mechanistic plausibility for sunitinib's anti-angiogenic and anti-proliferative activity to extend into this tumour type. This is not purely theoretical: two independent completed Phase 2 trials have directly tested sunitinib in non-GIST sarcoma populations (including liposarcoma) and observed response signals, and a Tier-1 Phase 2 publication specifically evaluated sunitinib in relapsed/refractory liposarcoma, leiomyosarcoma, and malignant fibrous histiocytoma.

Because sunitinib's core anti-VEGFR/PDGFR mechanism is shared across its approved oncology indications and the proposed new indication, the repurposing hypothesis is biologically coherent rather than a purely data-driven correlation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00474994	Phase 2	Completed	53	Multicenter continuous-dosing study of sunitinib in non-GIST sarcomas, including liposarcoma; direct evaluation of sunitinib's antitumour and antiangiogenic activity
NCT00400569	Phase 2	Completed	48	Open-label trial of sunitinib malate in metastatic/unresectable soft tissue sarcoma (leiomyosarcoma, liposarcoma, fibrosarcoma, MFH); dosed until progression or toxicity
NCT02048371	Phase 2	Completed	131	SARC024 study of oral regorafenib (not sunitinib) in selected sarcoma subtypes; cites sunitinib's activity in soft tissue sarcoma as rationale for the class — indirect supporting evidence only

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21154746	2011	RCT/Phase 2 trial	International Journal of Cancer	Single-institution Phase 2 study of sunitinib malate in relapsed/refractory soft tissue sarcoma, focused on leiomyosarcoma, liposarcoma, and MFH; assessed safety and efficacy
38254762	2024	Review	Cancers	Reviews genetic, epigenetic, and transcriptomic alterations in liposarcoma to guide targeted therapy selection
24712007	2014	Review	Magyar Onkológia	Reviews medical treatment of soft tissue sarcoma by histological subtype, including established and emerging targeted agents
24555529	2014	Review	Expert Review of Anticancer Therapy	Reviews emerging therapies for adult soft tissue sarcoma, including subtype-specific drug sensitivity
22987955	2012	Review	Annals of Oncology	Discusses histology-driven therapy for soft tissue sarcoma; notes exceptionally high trabectedin activity in myxoid liposarcoma and related targeted approaches
28423517	2017	Review/genomic	Oncotarget	Next-generation sequencing of extraskeletal myxoid chondrosarcoma; evaluates predictive factors for sunitinib benefit in a subset of patients
38717131	2024	Case series	American Journal of Surgical Pathology	Clinicopathologic analysis of 25 cases of a distinctive myofibroblastic sarcoma subtype with targetable molecular alterations
23482782	2013	Case report	Anticancer Research	Long-lasting clinical benefit of sunitinib malate in a heavily pretreated patient with metastatic liposarcoma
25884155	2015	Trial protocol (regorafenib)	BMC Cancer	REGOSARC trial protocol for regorafenib in advanced soft tissue sarcoma; cites sunitinib's role in sarcoma angiogenesis biology as background rationale

Germany Market Information

Sunitinib currently has no marketing authorizations on record in this jurisdiction (market status: Not Marketed; 0 authorizations). No product-level licensing data is available for review.

Cytotoxicity

Sunitinib is an antineoplastic agent, originally developed and approved for oncology indications (GIST, advanced renal cell carcinoma, pancreatic neuroendocrine tumour), which brings this section into scope.

Item	Content
Cytotoxicity Classification	Targeted therapy (multi-targeted receptor tyrosine kinase inhibitor: VEGFR1-3, PDGFRα/β, KIT, FLT3, RET)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two completed Phase 2 trials directly tested sunitinib in non-GIST soft tissue sarcoma populations including liposarcoma, and one Tier-1 Phase 2 publication specifically evaluated sunitinib in relapsed/refractory liposarcoma with a documented mechanistic basis (VEGFR/PDGFR inhibition). This is direct clinical evidence rather than model prediction alone, but it falls short of confirmatory randomized comparative data, so cautious, guardrail-bound advancement is appropriate rather than unrestricted "Go."

To proceed, the following is needed:

Local regulatory data (approval status, licensed indications, dosage forms) since the drug is currently not marketed in this jurisdiction
Mechanism-of-action documentation from DrugBank or the manufacturer's product information
Local package insert warnings, contraindications, and drug interaction data (currently unavailable)
A confirmatory, ideally randomized, trial specifically in liposarcoma populations to validate the signal seen in earlier non-GIST sarcoma studies
Toxicity/monitoring data specific to this drug (e.g., myelosuppression, cardiovascular, hepatic) to complete the cytotoxicity risk profile
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.